Advagene Biopharma Co (ROCO:6709) Long-Term Debt: NT$0.00 Mil (As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

ROCO:6709 Advagene Biopharma Co Ltd ROCO:6709
31 GF Score
Price NT$23.30
! 2 Warning Signs
View Full Analysis

What is Advagene Biopharma Co Long-Term Debt?

Advagene Biopharma Co ROCO:6709 31 Long-Term Debt is NT$0.00 Mil as of Dec. 2025. GuruFocus rates ROCO:6709 with a GF Score™ of 31/100. The stock has 2 warning signs investors should review.

Advagene Biopharma Co's Long-Term Debt for the quarter that ended in Dec. 2025 was NT$0.00 Mil.

Advagene Biopharma Co  (ROCO:6709) Long-Term Debt Explanation

Long-Term Debt is the sum of the carrying values as of the balance sheet date of all long-term debt, which is debt initially having maturities due after one year or beyond the operating cycle, if longer, but excluding the portions thereof scheduled to be repaid within one year or the normal operating cycle, if longer. Long-Term Debt includes notes payable, bonds payable, mortgage loans, convertible debt, subordinated debt and other types of long term debt.

Advagene Biopharma Co Long-Term Debt Related Terms

Advagene Biopharma Co Long-Term Debt Historical Data

* Premium members only.

The historical data trend for Advagene Biopharma Co's Long-Term Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Advagene Biopharma Co Long-Term Debt Chart

Advagene Biopharma Co Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Long-Term Debt
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

Advagene Biopharma Co Semi-Annual Data
Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Long-Term Debt Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
ROCO:6709
31GF Score
Advagene Biopharma Co Ltd ROCO:6709
Long-Term Debt is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
Frequently Asked Questions Learn more about Long-Term Debt →
What does a Long-Term Debt of NT$0.00 Mil mean?
Advagene Biopharma Co (ROCO:6709) has a Long-Term Debt of NT$0.00 Mil as of Dec. 2025.
Is Advagene Biopharma Co's Long-Term Debt too high?
Advagene Biopharma Co's current Long-Term Debt is NT$0.00 Mil. Overall, Advagene Biopharma Co has a GF Score™ of 31/100, reflecting its overall financial health beyond just this single metric.
How does Advagene Biopharma Co's Long-Term Debt compare to VRTX and REGN?
Advagene Biopharma Co's Long-Term Debt of NT$0.00 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Long-Term Debt for a Biotechnology company?
A good Long-Term Debt depends on the Biotechnology industry context. However, Long-Term Debt should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Long-Term Debt mean?
A high Long-Term Debt can signal that a stock is expensive relative to its fundamentals. Advagene Biopharma Co's current Long-Term Debt is NT$0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Advagene Biopharma Co stock overvalued right now?
Advagene Biopharma Co (ROCO:6709) has a current Long-Term Debt of NT$0.00 Mil. The current Long-Term Debt is NT$0.00 Mil. Advagene Biopharma Co's overall GF Score™ is 31/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Long-Term Debt calculated?
Long-Term Debt is calculated from a company's financial statements. For Advagene Biopharma Co (ROCO:6709), the current Long-Term Debt is NT$0.00 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Advagene Biopharma Co Business Description

Address Sector 1, Neihu Road, 6 Floor, No.308, Neihu District, Taipei, TWN, 114
Advagene Biopharma Co Ltd is a Taiwan based immune-modulatory platform-based biotechnology company. The company has completed technology transfer with DCB for detoxified LT Adjuvant Technology Platform. Its product development includes nasal spray seasonal flu vaccine, nasal spray COVID-19 vaccine, Immunotherapy for COVID-19, Respiratory Allergy Immunotherapy - Allergic Rhinitis and Asthma ,and other vaccines.
31GF Score

Get the complete analysis for ROCO:6709

Long-Term Debt is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

NT$23.30
Price